Clinical Trials Logo

Breast Neoplasms clinical trials

View clinical trials related to Breast Neoplasms.

Filter by:

NCT ID: NCT05089292 Completed - Screening Mammogram Clinical Trials

Increasing Breast Cancer Screening in Chinese Immigrants

Start date: July 1, 2021
Phase: N/A
Study type: Interventional

The long-term goal of this research is to increase breast cancer screening rates in NYC Chinese immigrants. The researchers plan to accomplish this objective by developing and testing a culturally- and linguistically-adapted Witness Project program for Chinese immigrants. To inform the intervention development, the study team will identify barriers and facilitators to breast cancer screening in Chinese immigrants through individual qualitative interviews. A total of 156 participants will be recruited during the entire study. In Aim 1 which started in July 2021, 60 women were recruited for in-depth interviews to assess their breast cancer knowledge, perceived barriers and benefits/risks to completing mammography, perceived susceptibility to breast cancer, fatalism, screening intention, acculturation, language preference, and health literacy. In Aim 2, 96 women will be recruited to participate in the pilot testing of the intervention. Recruitment will take place at community sites that serve Chinese immigrants in New York City. Enrollment for Aim 2 is anticipated to start in March of 2022.

NCT ID: NCT05085678 Completed - Breast Cancer Clinical Trials

Co'Moon for Supporting Breast Cancer Patients on Adjuvant Endocrine Therapy

Start date: December 1, 2020
Phase: N/A
Study type: Interventional

The objective of the study is to evaluate the effect of an online tool, based on patient reported outcomes (Co'moon), on the quality of life of breast cancer patients on adjuvant endocrine therapy in the University Hospital Leuven.

NCT ID: NCT05082740 Completed - Breast Cancer Risk Clinical Trials

FH-Risk 2.0: Updating Breast Cancer Risk Estimates

Start date: March 1, 2022
Phase:
Study type: Observational

In the UK women with a strong family history of breast cancer are eligible for breast cancer risk estimation via Family History Risk and Prevention Clinics (FHRPCs). Here breast cancer risk is calculated using popular risk prediction models like the Tyrer-Cuzick, CanRisk or Gail models. These models combine breast cancer risk factors to calculate a risk estimate for women. Risk factors include, family history, hormonal and reproductive factors, and risk factors related to health behaviours, for example, smoking, exercise and alcohol intake. Recently, risk estimation for breast cancer has become more accurate with the inclusion of mammographic density and Single Nucleotide Polymorphisms (SNPs) into popular risk prediction models. The addition of these new risk factors could alter the risk estimates that women in FHRPCs have been provided. How much these new risk factors alter a previously given risk estimate is unknown. It is also unknown how women will react to a revised risk estimate, especially if it changes their previous estimate and their access to preventive management options. This research aims to explore this gap in the literature.

NCT ID: NCT05079074 Completed - Clinical trials for Metastatic Breast Cancer

Clinical Application of Circulating Tumor DNA (ctDNA) in Patients With Late-stage Breast Cancer

ACTDNA
Start date: December 1, 2016
Phase:
Study type: Observational

This is a retrospective, observational, multi-center clinical study of circulating tumor DNA (ctDNA) application in late-stage breast cancers.

NCT ID: NCT05073432 Completed - Breast Cancer Clinical Trials

Development of a Personalized Discussion Prioritization Tool for Older Adults Considering Adjuvant Chemotherapy for Breast Cancer

Start date: July 28, 2021
Phase: Phase 1
Study type: Interventional

The investigators have developed a Discussion Prioritization Tool (DPT) for older adults consider adjuvant chemotherapy that utilizes Conjoint Analysis (CA) methodology and the objective of the current study is to assess usability of this DPT in the target population, older adults with breast cancer and to adapt the tool to optimize usability for the target population.

NCT ID: NCT05071677 Completed - Clinical trials for Anatomic Stage III Breast Cancer AJCC v8

Treatment Decision Making in African American Women Diagnosed With Triple Negative Breast Cancer

Start date: May 3, 2021
Phase:
Study type: Observational

This study evaluates what influences treatment decision-making in African American women with triple negative breast cancer. The study also aims to learn about the influence of information sources that support this decision-making process.

NCT ID: NCT05071560 Completed - Breast Cancer Clinical Trials

Physical Exercise for Breast Cancer Survivors: Face-to-face Versus Home-based

On4Rehab
Start date: May 1, 2021
Phase: N/A
Study type: Interventional

The present investigation is a pilot feasibility study that aims to compare a physical exercise intervention in a face-to-face context (considered state of the art) with a physical exercise intervention in a distance context (online), both supervised, in women, of legal age, physically inactive, breast cancer survivors after primary treatment with curative intent. Before and after the intervention these women will have a physical and functional assessment, as well as a pre-trial cardiopulmonary exercise test, to check if there are safety conditions to participate and also to self tailor the exercise prescription. The prescription follows the ACSM´s exercise guidelines for cancer survivors and will comprise a 8 week combined exercise training, 3 times per week, in which two of them will be supervised and the third session of the week (cardio session) won´t. Chat´s and weekly personal messages, as well as education, will be used to promote retention and exercise adherence.

NCT ID: NCT05058495 Completed - Clinical trials for Breast Cancer Related Lymphedema

The Effect of Mobile Lymphedema Self-Care Support Program on Self-Care in Women With Breast Cancer-related Lymphedema

Start date: September 1, 2021
Phase: N/A
Study type: Interventional

The aim of this randomized controlled study is to evaluate the effect of the mobile lymphedema self-care support program on self-care, quality of life and symptoms related to lymphedema in women with breast cancer-related lymphedema. H1: There is a difference between the Lymphedema Self-Care Scale mean score in women who develop lymphedema due to breast cancer, according to the use of the mobile lymphedema self-care support program. H2: There is a difference between the Lymphedema Quality of Life Scale average score in women who develop lymphedema due to breast cancer according to the status of using the mobile lymphedema self-care support program. H4: There is a difference between lymphedema arm circumference measurements according to the use of the mobile lymphedema self-care support program in women who develop lymphedema due to breast cancer. H5: In women who develop lymphedema due to breast cancer, there is a difference in the situation of experiencing symptoms related to lymphedema according to the use of the mobile lymphedema self-care support program.

NCT ID: NCT05057078 Completed - Breast Cancer Clinical Trials

The Effect of Mindfulness Program on Spiritual Well-BeingBreast Cancer Patients

Start date: September 29, 2021
Phase: N/A
Study type: Interventional

Breast cancer ranks first among the cancers seen in women in the World. Due to breast cancer, patients experience spiritual distress. The aim of this study is to determine the effect of mindfulness-based stress reduction program applied to patients with breast cancer on spiritual well-being.

NCT ID: NCT05054374 Completed - Breast Cancer Clinical Trials

A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer

Start date: September 14, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study to find out whether mirdametinib is a safe treatment for people with advanced solid tumor cancer that has certain mutations. Researchers will look at whether mirdametinib on its own or in combination with the drug fulvestrant is a safe treatment that causes few or mild side effects in people with advanced solid tumor cancer.